Biotech | April 25, 2022
CanSinoBIO rebrands to reflect commitment to life sciences research
This is the first major brand refresh of CanSinoBIO since its inception in 2009
This is the first major brand refresh of CanSinoBIO since its inception in 2009
Investment and innovation opportunities in the field of AYUSH are limitless : Sarbananda Sonowal
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
Under the agreement, Porton Advanced will provide services to accelerate the development, production and registration of breakthrough cell therapies currently being developed by Sinorda Biomedicine
With one of the most diverse lung cancer development programs, Novartis is focused on investments to advance the science, drive treatment and make an impact on patients
The proposed life sciences research and development centre in North of England region of UK will support acceleration of the company’s research in the areas of biotechnology, health and life sciences
Healthium Medtech, a company focused on products used in surgical, post-surgical and chronic care has ramped up its play in the global healthcare industry. In an interview with Thomas C. Thottathil, Editor, Indian Pharma Post, Anish Bafna, CEO and MD, Healthium Medtech outlines his plans
This recommendation is based on new data from two randomized controlled trials involving 3078 patients
The Phase 3 trial will be conducted under the auspices of the first Regenerative Medicine Advanced Therapy (RMAT) designation approved by the USFDA for an EV therapeutic
Within a fortnight, over 200 contestants sent their entries for the competition, and 30 names were shortlisted after screening entries under different categories
Subscribe To Our Newsletter & Stay Updated
